Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 13;8(2):e000981. doi: 10.1136/jitc-2020-000981

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Preconditioning with cyclophosphamide (CTX) focuses vaccine-induced immunity against the tumor. Frequency of (A) anti-ovalbumin (OVA) interferon γ (IFNγ)⁺, (B) anti-dopachrome tautomerase (DCT) IFNγ⁺, (C) anti-OVA IFNγ⁺ tumor necrosis factor α (TNFα)⁺ and (D) anti-DCT IFNγ⁺ TNFα⁺ CD8⁺ T-cells isolated from mediastinal lymph nodes draining melanoma lung metastases. Frequency of splenic (E) anti-OVA IFNγ⁺, (F) anti-DCT IFNγ⁺, (G) anti-OVA IFNγ⁺ TNFα⁺ and (H) anti-DCT IFNγ⁺ TNFα⁺ CD8⁺ T-cells. Frequency of splenic (I) anti-OVA and (J) anti-DCT IFNγ⁺ CD4⁺ T-cells. Samples harvested 9 days after co-vaccination with Ad-DCT and Ad-OVA with or without CTX preconditioning in mice bearing disseminated B16-F10 melanoma lung tumors. Data display mean±SD of one representative experiment.